Figure 5
Immunohistochemical (IHC) analysis of RFC2 protein expression in Pca tissues. (A–D) Representative IHC images of RFC2 in Pca tissues. (A) Positive (anti-RFC2 antibody) and negative control (non-specific rabbit IgG antibody) using bladder cancer specimens. (B) Anti-RFC2 in benign prostate, intensity score 0. (C) Anti-RFC2 in Pca, intensity score 1 and 2. (D) Anti-RFC2 in CRPC, intensity score 3. Scale bar = 50 μm. (E) Rate of cases in which positive IR was detected by RFC2 IHC in benign (N = 12), Pca (N = 103), and CRPC (N = 15) tissues. Chi-squared test was done to calculate P-value. IR scores of 0‐4 and 5–8 were defined as low and high IR, respectively. (F,G) High immunoreactivity (IR) score of RFC2 is associated with poor prognosis of prostate cancer patients. Progression-free survival (F) and cancer-specific survival (G) of prostate cancer patients are shown (N = 103). Survival curve was obtained by Kaplan–Meier method and P-value was determined by log-rank (Mantel–Cox) test. (H) Evaluation of the time to CRPC diagnosis in CRPC cases (N = 15). The median follow-up time from radical prostatectomy to CRPC diagnosis was summarized in CRPC cases with low and high RFC2 IR. Mann–Whitney test was done to calculate P-value.
